Truist Securities Reiterates Buy on Cormedix, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained the price target of $18 for the company's stock.
November 15, 2023 | 6:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reaffirmed a Buy rating on Cormedix with a maintained price target of $18, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst like Joon Lee can instill confidence in investors and potentially lead to a positive short term impact on Cormedix's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100